Short Interest: ULURU INCORPORATED NEW (OTCMKTS:ULUR) Shorted Shares Decreased By 51.16%

November 18, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest: ULURU INCORPORATED NEW (OTCMKTS:ULUR) Shorted Shares Decreased By 51.16%

The stock of ULURU INCORPORATED NEW (OTCMKTS:ULUR) registered a decrease of 51.16% in short interest. ULUR’s total short interest was 2,100 shares in November as published by FINRA. Its down 51.16% from 4,300 shares, reported previously. About 31,500 shares traded hands. Uluru Inc (OTCMKTS:ULUR) has declined 20.00% since April 18, 2016 and is downtrending. It has underperformed by 24.43% the S&P500.

ULURU Inc. is a specialty pharmaceutical firm focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The company has a market cap of $4.41 million. The Firm operates through the research, development and commercialization of pharmaceutical products segment. It currently has negative earnings. Utilizing its technologies, three of its products have been approved for marketing in various global markets.

ULUR Company Profile

ULURU Inc., incorporated on October 17, 1987, is a specialty pharmaceutical firm focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Firm operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as partial thickness burns, donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved by the Food and Drug Administration (FDA) for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.

More notable recent Uluru Inc (OTCMKTS:ULUR) news were published by: Prnewswire.com which released: “ULURU Inc. Reports Financial Results For Third Quarter 2016” on November 14, 2016, also Reuters.com with their article: “BRIEF-ULURU Inc reports Q3 loss per share $0.01” published on November 14, 2016, Prnewswire.com published: “ULURU Inc. Signs Cooperation Agreement For Japan” on June 02, 2016. More interesting news about Uluru Inc (OTCMKTS:ULUR) were released by: Prnewswire.com and their article: “ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending …” published on March 31, 2016 as well as Prnewswire.com‘s news article titled: “ULURU Inc. Announces The Acquisition Of Altrazeal Trading GmbH” with publication date: May 14, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>